The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing receptor (CaSR) mutation: Relevance to autosomal dominant hypocalcemia type 1 (ADH1)

Fadil M. Hannan, Gerard V. Walls, Valerie N. Babinsky, M. Andrew Nesbit, Enikö Kallay, Tertius A. Hough, William D. Fraser, Roger D. Cox, Jianxin Hu, Allen M. Spiegel, Rajesh V. Thakker

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, in appropriately low serum PTH con centrations and hyper calciuria. Negative all osteric Ca SR modulators, known as calcilytics, have been shown to normalize the gain-of-function associated with ADH-causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1-associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was determinedbyflow cytometry. NPS 2143 wasalso administered as a sing le ip bolus to wild-type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of amousemodel withanactivating CaSR mutation demonstrate NPS2143 to normalize the gain-of-function causing ADH1 and improve the hypocalcemia associated with this disorder.

Original languageEnglish (US)
Pages (from-to)3114-3121
Number of pages8
JournalEndocrinology
Volume156
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Calcium-Sensing Receptors
Hypocalcemia
Calcium
Mutation
HEK293 Cells
Intraperitoneal Injections
Familial Hypercalciuric Hypocalcemia
N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamine
Therapeutics
Serum
Pharmaceutical Preparations
In Vitro Techniques

ASJC Scopus subject areas

  • Endocrinology

Cite this

The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing receptor (CaSR) mutation : Relevance to autosomal dominant hypocalcemia type 1 (ADH1). / Hannan, Fadil M.; Walls, Gerard V.; Babinsky, Valerie N.; Nesbit, M. Andrew; Kallay, Enikö; Hough, Tertius A.; Fraser, William D.; Cox, Roger D.; Hu, Jianxin; Spiegel, Allen M.; Thakker, Rajesh V.

In: Endocrinology, Vol. 156, No. 9, 01.09.2015, p. 3114-3121.

Research output: Contribution to journalArticle

Hannan, Fadil M. ; Walls, Gerard V. ; Babinsky, Valerie N. ; Nesbit, M. Andrew ; Kallay, Enikö ; Hough, Tertius A. ; Fraser, William D. ; Cox, Roger D. ; Hu, Jianxin ; Spiegel, Allen M. ; Thakker, Rajesh V. / The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing receptor (CaSR) mutation : Relevance to autosomal dominant hypocalcemia type 1 (ADH1). In: Endocrinology. 2015 ; Vol. 156, No. 9. pp. 3114-3121.
@article{ee5a493d071142f2a711308f8c1bdf2c,
title = "The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing receptor (CaSR) mutation: Relevance to autosomal dominant hypocalcemia type 1 (ADH1)",
abstract = "Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, in appropriately low serum PTH con centrations and hyper calciuria. Negative all osteric Ca SR modulators, known as calcilytics, have been shown to normalize the gain-of-function associated with ADH-causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1-associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was determinedbyflow cytometry. NPS 2143 wasalso administered as a sing le ip bolus to wild-type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of amousemodel withanactivating CaSR mutation demonstrate NPS2143 to normalize the gain-of-function causing ADH1 and improve the hypocalcemia associated with this disorder.",
author = "Hannan, {Fadil M.} and Walls, {Gerard V.} and Babinsky, {Valerie N.} and Nesbit, {M. Andrew} and Enik{\"o} Kallay and Hough, {Tertius A.} and Fraser, {William D.} and Cox, {Roger D.} and Jianxin Hu and Spiegel, {Allen M.} and Thakker, {Rajesh V.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1210/en.2015-1269",
language = "English (US)",
volume = "156",
pages = "3114--3121",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing receptor (CaSR) mutation

T2 - Relevance to autosomal dominant hypocalcemia type 1 (ADH1)

AU - Hannan, Fadil M.

AU - Walls, Gerard V.

AU - Babinsky, Valerie N.

AU - Nesbit, M. Andrew

AU - Kallay, Enikö

AU - Hough, Tertius A.

AU - Fraser, William D.

AU - Cox, Roger D.

AU - Hu, Jianxin

AU - Spiegel, Allen M.

AU - Thakker, Rajesh V.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, in appropriately low serum PTH con centrations and hyper calciuria. Negative all osteric Ca SR modulators, known as calcilytics, have been shown to normalize the gain-of-function associated with ADH-causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1-associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was determinedbyflow cytometry. NPS 2143 wasalso administered as a sing le ip bolus to wild-type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of amousemodel withanactivating CaSR mutation demonstrate NPS2143 to normalize the gain-of-function causing ADH1 and improve the hypocalcemia associated with this disorder.

AB - Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, in appropriately low serum PTH con centrations and hyper calciuria. Negative all osteric Ca SR modulators, known as calcilytics, have been shown to normalize the gain-of-function associated with ADH-causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1-associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was determinedbyflow cytometry. NPS 2143 wasalso administered as a sing le ip bolus to wild-type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of amousemodel withanactivating CaSR mutation demonstrate NPS2143 to normalize the gain-of-function causing ADH1 and improve the hypocalcemia associated with this disorder.

UR - http://www.scopus.com/inward/record.url?scp=84942745639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942745639&partnerID=8YFLogxK

U2 - 10.1210/en.2015-1269

DO - 10.1210/en.2015-1269

M3 - Article

C2 - 26052899

AN - SCOPUS:84942745639

VL - 156

SP - 3114

EP - 3121

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 9

ER -